Afterwards, pembrolizumab received approval from the Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic CC with disease progression during or after chemotherapy (whose tumours express PD-L1) based on the objective response rate and durability of responses [67]. This evidence concerns the gene CD274 and neoplasm.